Why Clarity Pharmaceuticals, EOS, Nuix, and Reece shares are racing higher today

It has been a tough start to the week for the S&P/ASX 200 Index (ASX: XJO). In afternoon trade, the benchmark index is down 0.5% to 9,038.2 points.

Four ASX shares that are not letting that hold them back are listed below. Here’s why they are rising:

Clarity Pharmaceuticals Ltd (ASX: CU6)

The Clarity Pharmaceuticals share price is up 12% to $3.92. This morning, the company announced another patient in its SECuRE Phase II trial achieved undetectable disease following treatment with its 67Cu-SAR-bisPSMA therapy. Clarity’s executive chair, Dr Alan Taylor, said: “The momentum of data we are generating with our lead SAR-bisPSMA product in both theranostic and diagnostic trials is strong, with excellent results to date on all fronts. We are beyond excited to see yet another patient achieve undetectable disease following their 67Cu-SAR-bisPSMA treatments.”

Electro Optic Systems Holdings Ltd (ASX: EOS)

The EOS share price is up 17% to $8.57. This follows the release of the defence company’s FY 2025 results. EOS reported revenue from continuing operations of $128.5 million, which is down 27% year on year. However, looking ahead, management revealed that its unconditional order book stood at $459 million on 31 December 2025. This is up 238% from $136 million a year earlier. Importantly, EOS aims to realise 40% to 50% of the current order book during 2026.

Nuix Ltd (ASX: NXL)

The Nuix share price is up 16% to $1.58. Investors have been buying this investigative analytics and intelligence software provider’s shares after it released its half-year results. Nuix reported an 8.4% increase in annualised contract value (ACV) to $234.4 million. A key driver of this has been the Nuix Neo offering, which reported ACV growth of 148% year on year to $46.8 million. It now represents 20% of the company’s total ACV. Commenting on the AI threat, Nuix’s interim CEO, John Ruthven, said: “The rapidly evolving AI landscape presents both challenges and opportunities for enterprise software companies. Nuix is well positioned to capitalise on these dynamics through our BYO AI framework, which allows customers to integrate their preferred AI models whilst Nuix Neo provides the critical enterprise infrastructure required by regulated industries.”

Reece Ltd (ASX: REH)

The Reece share price is up 16% to $16.15. This follows the release of the plumbing parts company’s half-year results. Reece reported a 6% increase in revenue to $4,648 million but a 20% decline in net profit after tax to $144 million. The latter is better than Morgans was expecting. It was forecasting a 22.9% decline in net profit to $139.5 million.

The post Why Clarity Pharmaceuticals, EOS, Nuix, and Reece shares are racing higher today appeared first on The Motley Fool Australia.

More reading

• Why are ASX 300 tech stock Nuix shares jumping 27% in Monday’s falling market?
• Why are EOS shares rocketing 17% today?
• Why is this ASX 300 stock jumping 14% on Monday?
• Reece HY26 results: Profit falls despite higher sales revenue
• 5 things to watch on the ASX 200 on Monday

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Electro Optic Systems. The Motley Fool Australia has recommended Nuix. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.